Privacy-safe target audiences of ideal patients that are higher in audience quality and drive increased script lift
Swoop empowers the world’s leading healthcare and life sciences organizations to better educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey. Swoop’s HIPAA-certified and NAI-accredited system of insight has already uncovered over 500 unique target audiences for precisely engaging ideal patient populations through cross-channel marketing strategies by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world evidence pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions.
Real world insights to pinpoint the ideal patient and their healthcare ecosystem
IPM.ai empowers the world’s leading pharmaceutical and biopharmaceutical companies to better understand and improve the lives of patients through the research, development and commercialization of new therapies and modalities of care. IPM.ai’s HIPAA-certified system of insight streamlines patient discovery, treatment journey mapping, referral network intelligence, key opinion leader identification, market segmentation and adherence modeling by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world evidence and outcomes research pool of over 300 million de-identified patients.
The Swoop AI Advantage
ML and AI for Audience Targeting
Swoop uses cutting-edge AI and robust deidentified health and demographic data sets to build targeting segments for both sensitive and non-sensitive conditions. With the capability to build segments using no inferred health knowledge of any kind, Swoop can satisfy your and the industry’s most stringent privacy requirements.
ML and AI for Patient Finding
Speciality and rare diseases present a unique challenge. With both diagnosis rate and disease awareness among patients and HCPs being extremely low, simply identifying the appropriate market can be incredibly difficult. IPM.ai’s unique ability to quickly integrate first-party data in a HIPAA-certified manner combined with our utilization of advanced AI and machine learning techniques, we can help pinpoint the affected patient population, associated HCPs and key influencers, as well as highlight milestones along the patient journey.
Our Dedication To Transparency And Privacy
Our granular-level longitudinal analytics, artificial intelligence and machine learning capabilities are applied to a real world evidence pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions. We maintain at all times a HIPAA attestation that our data pool and any resulting outputs from its analysis cannot be reidentified.
Privacy-Safe Audience Targeting
Swoop is extremely cognizant of the privacy concerns around audience-building, and is fully compliant with the Network Advertising Initiative’s 2020 Code of Conduct and the California Consumer Privacy Act. This includes the ability to build audience segments for any condition using no inferred health data of any kind, including no location data, purchase data or health data.
HIPAA-Certified Patient Finding
IPM.ai’s patent-pending architecture and data processing methodology has been HIPAA certified, uniquely positioning us to combine disparate data sets – including clients’ first-party data – without the need for a lengthy and expensive recertification process. This uniquely positions IPM.ai to solve the challenges presented by rare and orphan diseases.
Request A Quote For Audience Building
Interested in Swoop’s audience targeting? Curious about the audience we could build for you? Fill out the form to request data on available conditions, audience quality and how that translates to ROI-friendly CPM and volume.
In the News
The latest news and research from Swoop.
In the fight against COVID-19, doctors are innovating at a rapid rate. One focus of innovation has been hydroxychloroquine sulfate,